Assessment and treatment of pulmonary arterial hypertension: An Australian perspective in 2006

Internal Medicine Journal

Volumn 37, Issue 1, 2007, Pages 38-48

  Gabbay, E ^a   Reed, A ^b   Williams, T J ^b  

^a ROYAL PERTH HOSPITAL   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Pathogenesis; Pulmonary arterial hypertension; Pulmonary hypertension; Therapy

Indexed keywords

AMBRISENTAN; ANTIRETROVIRUS AGENT; BERAPROST; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; CYCLIC GMP; ENDOTHELIN; ENDOTHELIN RECEPTOR ANTAGONIST; ILOPROST; IMMUNOSUPPRESSIVE AGENT; NITRIC OXIDE; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN; PROSTANOID; SILDENAFIL; SITAXSENTAN; UNIPROST; VASODILATOR AGENT;

AMINOTRANSFERASE BLOOD LEVEL; AUSTRALIA; BLALOCK HANLON OPERATION; CLINICAL TRIAL; CONTINUOUS INFUSION; DIAGNOSTIC ACCURACY; DISEASE CLASSIFICATION; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SELECTIVITY; DRUG SUBSTITUTION; DYSPNEA; ECHOCARDIOGRAPHY; FLUSHING; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART CATHETERIZATION; HEART SURGERY; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INJECTION SITE PAIN; LIVER DYSFUNCTION; LIVER FUNCTION; LUNG ARTERY PRESSURE; LUNG BLOOD VESSEL; LUNG TRANSPLANTATION; LUNG VASCULAR RESISTANCE; OFF LABEL DRUG USE; PATHOGENESIS; PATIENT CARE; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; QUALITY OF LIFE; REVIEW; SEPSIS; SIDE EFFECT; STANDARD; SYMPTOM; VASCULAR DISEASE;

ADOLESCENT; ADULT; AGED; ARTERIOLES; AUSTRALIA; DIAGNOSTIC IMAGING; DISEASE PROGRESSION; DYSPNEA; EPOPROSTENOL; EXERCISE TEST; FEMALE; FORECASTING; HEART CATHETERIZATION; HEART-LUNG TRANSPLANTATION; HUMANS; HYPERTENSION, PULMONARY; ILOPROST; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; NITRIC OXIDE; PIPERAZINES; PROGNOSIS; PULMONARY ARTERY; RANDOMIZED CONTROLLED TRIALS; RECEPTOR, ENDOTHELIN A; SULFONAMIDES; VASCULAR RESISTANCE; VASODILATOR AGENTS; VENTRICULAR DYSFUNCTION, RIGHT;

EID: 33845567426     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2006.01242.x     Document Type: Review

References (50)

1. Rubin LJ. ACCP evidence-based clinical practice guidelines: diagnosis and management of pulmonary arterial hypertension. Chest 2004; 126: 1-92S.
2. Galie N. Guidelines on diagnosis and treatment of pulmonary arterial hypertension: the task force on diagnosis and treatment of pulmonary arterial hypertension of the European society of cardiology. Eur Heart J 2004; 25: 2243-78.
3. Runo JR, Loyd JE. Primary pulmonary hypertension. Lancet 2003; 361: 1533-44.
4. Gaine SP, Rubin LJ. Primary pulmonary hypertension [Published erratum appears in Lancet 1999; 353: 74]. Lancet 1998; 352: 719-25.
5. Simonneau G, Galie N, Rubin LJ, Langleben D, Seeger W, Domenighetti G et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004; 43(12 Suppl S): 5-12S.
6. Moser KM, Auger WR, Fedullo PF. Chronic major-vessel thromboembolic pulmonary hypertension. Circulation 1990; 81: 1735-43.
7. Bonderman D, Nowotny R, Skoro-Sajer N, Jakowitsch J, Adlbrecht C, Klepetko W et al. Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension. Chest 2005; 128: 2599-603.
8. Stewart S, Murphy NF, McMurray JJV, Strange G, Peacock A. Population-based analysis of pulmonary arterial hypertension in Scotland (1996-2001). Eur Respir J.
9. Rich S, Dantzker DR, Ayres SM, Bergofsky EH, Brundage BH, Detre KM et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med 1987; 107: 216-23.
10. Loyd JE, Butler MG, Foroud TM, Conneally PM, Phillips JA III, Newman JH. Genetic anticipation and abnormal gender ratio at birth in familial primary pulmonary hypertension. Am J Respir Crit Care Med 1995; 152: 93-97.
11. Lane KB, Machado RD, Pauciulo MW, Thomson JR, Phillips JA III, Loyd JE et al. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. The international PPH consortium. Nat Genet 2000; 26: 81-4.
12. Deng Z, Morse JH, Slager SL, Cuervo N, Moore KJ, Venetos G et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 2000; 67: 737-44.
13. Eddahibi S, Humbert M, Fadel E, Raffestin B, Darmon M, Capron F et al. Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J Clin Invest 2001; 108: 1141-50.
14. Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med 2004; 351: 1655-65.
15. Voelkel NF, Tuder RM, Weir EK. Pathophysiology of primary pulmonary hypertension: from physiology to molecular mechanisms. In: Rubin L, Rich S, eds. Primary Pulmonary Hypertension. New York: Marcel Decker; 1997; 83-129.
16. Herve P, Launay JM, Scrobohaci ML, Brenot F, Simonneau G, Petitpretz P et al. Increased plasma serotonin in primary pulmonary hypertension. Am J Med 1995; 99: 249-54.
17. Eddahibi S, Humbert M, Sediame S, Chouaid C, Partovian C, Maitre B et al. Platelet vascular endothelial growth factor and platelet-derived growth factor in pulmonary hypertension effect of prostacyclin therapy. Am J Respir Crit Care Med 2000; 162: 1493-9.
18. Yuan XJ, Wang J, Juhaszova M, Gaine SP, Rubin LJ. Attenuated K+ channel gene transcription in primary pulmonary hypertension. Lancet 1998; 351: 726-7.
19. Sanchez O, Sitbon O, Jais X, Simonneau G, Humbest M. Immunosuppresive therapy in connective tissue diseases-associated pulmonary arterial hypertension. Chest 2006; 130: 182-9.
20. Barst RJ, McGoon M, Torbicki A, Sitbon O, Krowka MJ, Olschewski H et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43(12 Suppl S): 40-47S.
21. Cheitlin MD, Armstrong WF, Aurigemma GP, Beller GA, Bierman FZ, Davis JL et al. American College of Cardiology, American Heart Association, American Society of Echocardiography: ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). Circulation 2003; 108: 1146-62.
22. Atwood CW Jr, McCrory D, Garcia JG, Abman SH, Ahearn GS. American College of Chest Physicians: pulmonary artery hypertension and sleep-disordered breathing: ACCP evidence-based clinical practice guidelines. Chest 2004; 126(1 Suppl S): 72-77S.
23. D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991; 115: 343-9.
24. Sitbon O, Humbert M, Jais X, Ioos V, Hamid AM, Provencher S et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005; 111: 3105-11.
25. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992; 327: 76-81.
26. Galie N, Seeger W, Naeije R, Simonneau G, Rubin LJ. Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43(12 Suppl S): 81-88S.
27. Rubin LJ, Mendoza J, Hood M, McGoon M, Barst R, Williams WB et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Intern Med 1990; 112: 485-91.
28. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The primary pulmonary hypertension study group. N Engl J Med 1996; 334: 296-302.
29. Simonneau G, Barst RJ, Galie N, Naeije R, Rich S, Bourge RC et al. Treprostinil study group: continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002; 165: 800-4.
30. Olschewski H, Simonneau G, Galie N, Higenbottam T, Naeije R, Rubin LJ et al. Aerosolized iloprost randomized study group: inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002; 347: 322-9.
31. Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001; 358: 1119-23.
32. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A et al. Bosentan therapy for pulmonary arterial hypertension [Published erratum appears in N Engl J Med 2002; 346: 1258]. N Engl J Med 2002; 346: 896-903.
33. Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D et al. Sildenafil use in pulmonary arterial hypertension (SUPER) study group: sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353: 2148-57.
34. Zapol WM, Falke KJ, Hurford WE, Roberts JD Jr. Inhaling nitric oxide: a selective pulmonary vasodilator and bronchodilator. Chest 1994; 105(3 Suppl S): 87-91S.
35. Sitbon O, Gressin V, Speich R, Opravil M, Macdonald PS, Cooper DA et al. Bosentan in pulmonary arterial hypertension associated with HIV infection. Eur Respir J 2003; 22: 563S.
36. Krowka MJ, Frantz RP, McGoon MD, Severson C, Plevak DJ, Wiesner RH. Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): a study of 15 patients with moderate to severe portopulmonary hypertension. Hepatology 1999; 30: 641-8.
37. Lin EE, Rodgers GP, Gladwin MT. Hemolytic anemia-associated pulmonary hypertension in sickle cell disease. Curr Hematol Rep 2005; 4: 117-25.
38. Mariette X, Brenot F, Brouet JC. Recovery from pulmonary hypertension with steroid therapy in a patient with Sjogren's syndrome and polymyositis. J Rheumatol 1994; 21: 772-3.
39. Opravil M, Pechere M, Speich R, Joller-Jemelka HI, Jenni R, Russi EW et al. HIV-associated primary pulmonary hypertension. A case control study. Swiss HIV cohort study. Am J Respir Crit Care Med 1997; 155: 990-95.
40. Minder S, Fischler M, Muellhaupt B, Zalunardo MP, Jenni R, Clavien PA et al. Intravenous iloprost bridging to orthotopic liver transplantation in portopulmonary hypertension. Eur Respir J 2004; 24: 703-7.
41. Schott R, Chaouat A, Launoy A, Pottecher T, Weitzenblum E. Improvement of pulmonary hypertension after liver transplantation. Chest 1999; 115: 1748-9.
42. Sandoval J, Gaspar J, Pulido T, Bautista E, Martinez-Guerra ML, Zeballos M et al. Graded balloon dilation atrial septostomy in severe primary pulmonary hypertension. A therapeutic alternative for patients nonresponsive to vasodilator treatment. J Am Coll Cardiol 1998; 32: 297-304.
43. Hertz MI, Boucek MM, Deng MC, Edwards LB, Keck BM, Kirklin JK et al. Scientific registry of the international society for heart and lung transplantation: introduction to the 2005 annual reports. J Heart Lung Transplant 2005; 24: 945-82.
44. Sitbon O, Humbert M, Nunes H, Parent F, Garcia G, Herve P et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002; 40: 780-88.
45. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002; 106: 1477-82.
46. McLaughlin VV, Sitbon O, Badesch DB, Barst RJ, Black C, Galie N et al. Survival with first-line bosentan in patients with primary pulmonary hypertension [Published erratum appears in Eur Respir J 2005; 25: 942]. Eur Respir J 2005; 25: 244-9.
47. McLaughlin VV, Presberg KW, Doyle RL, Abman SH, McCrory DC, Fortin T et al. American college of chest physicians: prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004; 126(1 Suppl S): 78-92S.
48. Hoeper MM, Taha N, Bekjarova A, Gatzke R, Spiekerkoetter E. Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids. Eur Respir J 2003; 22: 330-34.
49. Ghofrani HA, Rose F, Schermuly RT, Olschewski H, Wiedemann R, Kreckel A et al. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J Am Coll Cardiol 2003; 42: 158-64.
50. Newman JH, Fanburg BL, Archer SL, Badesch DB, Barst RJ, Garcia JG et al. Pulmonary arterial hypertension: future directions: report of a national heart, lung and blood institute/office of rare diseases workshop. Circulation 2004; 109: 2947-52.